CalciMedica can continue developing Auxora after the FDA reviewed KOURAGE safety data without imposing a clinical hold, but a large financing, major potential dilution and a strategic shift toward pulmonary hypertension redefine the CALC investment case.
Inhibikase Therapeutics begins pivotal Phase 3 testing of IKT-001 in PAH. Discover what this means for approval odds, clinicians, and investors.
Anumana won FDA clearance for an ECG-AI pulmonary hypertension tool. Read what it changes for diagnosis, workflow adoption, and cardiovascular AI strategy.
Gossamer Bio’s Phase 3 PROSERA data for seralutinib in PAH missed its primary endpoint. Read what this means for regulators and clinicians.
GSK is acquiring 35Pharma for $950 million to strengthen its pulmonary hypertension pipeline. Find out what HS235 changes and what risks remain.
Merck has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an expanded indication for WINREVAIR (sotatercept) in combination with other therapies for the treatment of pulmonary arterial hypertension (PAH) in adults across WHO Functional Classes II, III, and IV. The update follows pivotal